Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report.

Using more than one therapeutic approach in the treatment of basal cell carcinomas (BCCs) has the potential to enhance cure rates. In this study, 57 nodular and superficial BCCs were curetted without electrodesiccation. One week later, imiquimod 5% cream therapy was initiated once daily 5 times per week for 6 weeks. At 1-year follow-up, 0 of 57 BCCs (0%) had clinical recurrences. Cosmetic results were very good to excellent. Combination therapy with imiquimod 5% cream followed by curettage represents an effective method for treating BCCs with a high cure rate.